Changes in clinical condition of the eye and in parameters of cell and humoral immunity in iridocyclitis patients under the influence of anti-viral allokin-alpha
DOI:
https://doi.org/10.31288/oftalmolzh201661923Keywords:
iridocyclitis, allokin-alphaAbstract
Introduction. Iridocyclitis, inflammatory eye disease of the uvea, is a topical issue not only in clinical but social regard, considering its high prevalence and disability rates.
Purpose. To study changes in the clinical condition of the eye and the state of cellular and humoral immunity in iridocyclitis patients under the influence of allokin-alpha anti-viral drugs.
Material and Methods. We observed 41 patients (41 eyes) with acute and chronic iridocyclitis who underwent anti-viral allokin-alpha treatment at Inflammatory Eye Pathology Department at SI “The Filatov Institute of Eye Diseases and Tissue Therapy”.
Results. Over the treatment course we observed a significant increase in immunoregulatory index from 1.16% to 2.00%; a relative T-lymphocyte count increased from 38.2±0.5% to 63.4±1.2% and a relative CD-19 lymphocyte count decreased from 24.4% to 21.8%, which reached normal parameters at 18 days after treatment onset. The treatment resulted in VA improvement.
Conclusions. Using allokin-alpha anti-viral drug enables to raise treatment success in viral iridocyclitis patients and to improve VA against the background of inflammatory process reduction.
References
1. Barinskii IF. [Herpesviral infections - immunodeficient diseases of the XXI century. Current issues of herpesviral infections]. 2004:5-7. Russian.
2. Guliieva M. [Experimental and clinical studies of Oftalmoferon eye drops in the herpetic keratitis treatment]. Author's thesis for Cand. Sc. (Med.). 14.00.08 Ophthalmology. M.; 2006. 30 p. Russian.
3. Degtyarenko TV. [Adaptive significance of immune homeostasis in eye diseases]. Oftalmol Zh. 1997;1:1-4. Russian.
4. Drozdova EA, Tarasova LN, Teplova SN, Alekhina TV. [Immunological features of uveitis in systemic diseases]. Vestn Oftalmol. 2004;4:24-6. Russian.
5. Zainutdinova GKh, Malkhanov VB, Shevchuk NE. [Features of systemic and local cytokine production in rheumatoid uveitis]. Tsitokiny i vospaleniie. 2008;7(2):52-5. Russian.
6. Исаков В.А. Герпеcвирусные инфекции человека / В.А. Исаков, Е.И. Архипов, Д.В. Исаков // Руководство для врачей . - СПб.:СпецЛит., 2006. - 303 с.
7. Metelitsyna IP, Levitska GV, Ghaffari Sahbi ben Mohamed Moncef. [The level of cytokines in intraocular fluids in patients with rhegmatogenous retinal detachment]. Odeskyi Med. Zhurnal. 2011; 4(126):37-9. Ukrainian.
8. Sukhina LA, Lysenko AG, Yulish ME. [Optimizing the diagnosis and treatment of chronic recurrent uveitis in children caused by persistent intracellular infections]. Oftalmologiia. Vostochnaia Evropa. 2014;2(21):20-6.] Ruaaian.
9. Khokkanen VM, Solovieva MV, Bataiev VM, Ionova OG. [Investigation of the role of cytokines in the course of tuberculous uveitis]. Collection of papers of scientific practical conference in ophthalmosurgery «East-West», 13-14 May 2011. Ufa, 2011. 350-352. Russian.
10. Shaimova VA. [The role of inflammatory cytokines in eye diseases]. (Litereature review). Oftalmokhirurgiia i terapiia. 2004;4(3):30-2. Russian.
11. Shishkin MK, Isakov VA, Iermolinko DK. Selected issues of infectious patient therapy: Guidance for physicians. SPb.: Foliant; 2005. 636-64. Russian.
12. Groot-Mijnes JDF, Groot-Mijnes L Visser, Zuurveen S et al. Identification of new pathogens in the intraocular fluid of patients with uveitis. Am. J. Ophthalmol. 2010;150 (5):628-36. https://doi.org/10.1016/j.ajo.2010.05.015
13. Plskova J, Greiner K, Forrester JV. Interferon-? as an effective treatment for noninfectious posterior uveitis and panuveitis. Am. J. Ophthalmol.2007;144: 55-61. https://doi.org/10.1016/j.ajo.2007.03.050
14. Takase H, Sugita S, Taguchi C et al. Capacity of ocular infiltrating T helper type 1 cells of patients with non-infectious uveitis to produce chemokines. Br. J. Ophthalmol.2006;90:765-8. https://doi.org/10.1136/bjo.2005.087353
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Н. В. Коновалова, Н. И. Храменко, Л. Н. Величко, А. Я. Новик
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows users to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.
COPYRIGHT NOTICE
Authors who publish in this journal agree to the following terms:
- Authors hold copyright immediately after publication of their works and retain publishing rights without any restrictions.
- The copyright commencement date complies the publication date of the issue, where the article is included in.
DEPOSIT POLICY
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) during the editorial process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work with an acknowledgement of its initial publication in this journal.
- Post-print (post-refereeing manuscript version) and publisher's PDF-version self-archiving is allowed.
- Archiving the pre-print (pre-refereeing manuscript version) not allowed.
